ArticleNeuromolecular medicine2026
Anti-Inflammatory Potential of Stearidonic Acid Ethanolamide in a Model of Mild Traumatic Brain Injury in Mice.
Article in Neuromolecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Chronic neuroinflammation is recognized as a pivotal mechanism responsible for secondary damage following mild traumatic brain injury (mTBI), underscoring the critical need for therapeutic strategies capable of mitigating this pathological process. This study evaluated the anti-inflammatory properties of stearidonic acid ethanolamide (SDEA, C20H33NO2). The findings indicate that mTBI triggers persistent neuroinflammation, which is correlated with cognitive deficits. A ten-day treatment regimen with SDEA at 10 mg/kg/day facilitated the restoration of cognitive abilities and suppressed the neuroinflammatory cascade in a mouse model. Memory impairments and anxiety-like behaviors were quantified through behavioral testing. Immunohistochemical techniques were employed to examine alterations in Iba-1-positive microglia and nNOS-positive cells within the cortical and hippocampal regions (CA1 and DG). The expression profiles of pro- and anti-inflammatory markers (IL1β, IL6, TNFα, CD68, CD206) were analyzed via reverse transcription polymerase chain reaction (RT-PCR) and Western blot. Furthermore, an in vitro model of LPS-induced inflammation in SIM-A9 microglial cells was utilized to investigate the impact of SDEA on the production of cytokines, reactive oxygen species (ROS), nitric oxide (NO), and nitrites. Integrative analysis of in vivo and in vitro data showed that SDEA: (1) improved behavioral deficits by reducing anxiety and improving working memory; (2) suppressed pro-inflammatory microglial activation and nNOS-positive cells; (3) lowered pro-inflammatory cytokine, ROS, NO, and nitrite concentrations; and (4) enhanced CD206 marker expression in the cerebral cortex. These collective findings underscore the therapeutic potential of SDEA for traumatic CNS injuries.
Indexed as
Identifiers
41504829What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.